Antag Therapeutics
Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders. Their approach is based on pioneering research from the University of Copenhagen, focusing on incretin physiology. They develop GIPR antagonist therapies inspired by an endogenous GIPR antagonist discovered by Professors Jens Juul Holst and Mette Rosenkilde, with extensive human trial studies.
Industries
Nr. of Employees
small (1-50)
Antag Therapeutics
Copenhagen, Hovedstaden, Denmark, Europe
Patents
News & Updates
Antag Therapeutics announced the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of its GIP receptor antagonist AT-7687.
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity. The trial aims to induce weight loss without gastrointestinal side effects.
Joerg Moeller, MD, PhD, was appointed as CEO, succeeding co-founder Alexander Sparre-Ulrich.
The company announced the closing of an €80 million Series A financing round led by Versant Ventures, with participation from several investors.
FDA accepted the IND application for AT-7687, marking a major step in clinical development and the start of Phase I studies.
Dr. Fischette was appointed to the company's board.
Antag Therapeutics announced the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of its GIP receptor antagonist AT-7687.
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity. The trial aims to induce weight loss without gastrointestinal side effects.
Joerg Moeller, MD, PhD, was appointed as CEO, succeeding co-founder Alexander Sparre-Ulrich.
The company announced the closing of an €80 million Series A financing round led by Versant Ventures, with participation from several investors.
FDA accepted the IND application for AT-7687, marking a major step in clinical development and the start of Phase I studies.
Dr. Fischette was appointed to the company's board.